30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML Low frequency of differentiation syndrome, including 5% rate (1/20) of Grade 3 among NPM1-mutant patients treated at 600 mg 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive...

Kura Oncology, Inc. (NASDAQ:KURA Get Rating) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 6,980,000 shares, an increase of 11.0% from the October 31st total of 6,290,000 shares. Approximately 10....

In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the ...

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is ...

Kura Oncology, Inc. (NASDAQ:KURA Get Rating) Analysts at Wedbush lowered their FY2025 EPS estimates for Kura Oncology in a note issued to investors on Thursday, November 3rd. Wedbush analyst R. Driscoll now anticipates that the company will earn $2.40 per share for the year, down ...